Drug legislation 1976: cost analysis for the pharmaceutical industry
Kopf, R.
Der Internist 21(6): 333-338
1980
ISSN/ISBN: 0020-9554 PMID: 7005170 Document Number: 157850
Document emailed within 1 workday
Related Documents
Robinson, D.S. 1994: Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. a pharmaceutical industry perspective on drug labeling Psychopharmacology Bulletin 30(1): 23-25Gatty, B. 1994: Drug sampling: legislation proposed; industry receptive to ending practice Hospital Formulary 29(6): 478 477
Modestin, J. 1970: Psychotropic drug therapy and pharmaceutical industry Arzneimittel-Forschung 20(7): 877-879
Schacter, L.P.; Anderson, C.; Canetta, R.M.; Kelley, S.; Nicaise, C.; Onetto, N.; Rozencweig, M.; Smaldone, L.; Winograd, B. 1992: Drug discovery and development in the pharmaceutical industry Seminars in Oncology 19(6): 613-621
Personeus, G.R.; Ascione, P. 1981: Preparation and use of drug master files in the pharmaceutical industry Journal of Parenteral Science and Technology: a Publication of the Parenteral Drug Association 35(2): 63-69
Watkins, E.S. 2012: How the pill became a lifestyle drug: the pharmaceutical industry and birth control in the United States since 1960 American Journal of Public Health 102(8): 1462-1472
Salas, Sía.P.; Osorio F, M.; Vial C, P.; Rehbein V, A.María.; Salas A, C.; Beca I, J.Pablo. 2006: Conflicts of interest in clinical practice. Ethical analysis of some relationships with the pharmaceutical industry Revista Medica de Chile 134(12): 1576-1582
Spengler, D.M.; Bigos, S.J.; Martin, N.A.; Zeh, J.; Fisher, L.; Nachemson, A. 1986: Back injuries in industry: a retrospective study. I. Overview and cost analysis Spine 11(3): 241-245
Amédée-Manesme, O. 2000: Strategic analysis and the drug industry Therapie 55(2): 313-317
1982: Pharmaceutical Reimbursement Board; final maximum allowable cost (MAC) determinations for certain drug products--Health Care Financing Administration. Final notice Federal Register 47(251): 58370-58372
Nissanholtz-Gannot, R.; Yankellevich, A.; Nirel, N. 2016: The Influence of the Israeli Legislation on the Relationship Between Physicians and Pharmaceutical Companies Harefuah 155(7): 426-430
Calin, A. 1987: Drugs and the relationships between university, industry and legislation Drugs under Experimental and Clinical Research 13(11): 685-687
Cohen, A.F. 2005: The pharmaceutical industry in uproar Nederlands Tijdschrift Voor Geneeskunde 149(19): 1074
Schwarting, J.S. 2000: The pharmaceutical industry--to whom is it accountable? New England Journal of Medicine 343(19): 1416; Discussion 1417
Kahn, M.F. 1984: More on rheumatology and the pharmaceutical industry Journal of Rheumatology 11(5): 717-718
Walker, A.M.; García Rodríguez, L.A.; Pérez Gutthann, S. 1992: Epidemiology and the pharmaceutical industry Medicina Clinica 98(12): 465-468
Aumonier, J. 2003: Action of the pharmaceutical industry Annales Pharmaceutiques Francaises 61(6): 378-382
Andersen, K. 1975: The responsibility of the pharmaceutical industry Nordisk Medicin 90(4): 115
Brain, K.R. 1993: The implications of developments in pharmaceutical analysis and new medicines on pharmaceutical education Journal of Pharmacy and Pharmacology 45(Suppl 1): 381-383
Hermanowski, T.; Bystrov, V.; Staszewska-Bystrova, A.; Szafraniec-Buryło, S.I.; Rabczenko, D.; Kolasa, K.; Orlewska, E. 2015: Analysis of Trends in Life Expectancies and per Capita Gross Domestic Product as well as Pharmaceutical and Non-Pharmaceutical Healthcare Expenditures Acta Poloniae Pharmaceutica 72(5): 1045-1050